RE: There she goes17 Feb 2026 11:11
A puzzle to me is why a predator isn't circling.
At 10p (placing price) which seems a possibility, we would be valued at approx Β£14m. People say, why would a Pharma be interested whilst the tox studies are ongoing but, why wouldn't they if they see potential in the pipeline? At 50p (which, at the moment is "bite your hand off" territory for many) we are still only worth Β£70m which is back of the sofa money for the giants. Is it because Sareum has nothing to offer or tempt even at a low price? Could it be that 737 is dead in the water? Why can a Pharma not see a business case for an offer?
These AIM shares are bad for the health. 15/20 years of hope and despair. I see it so many times across the AIM. People hanging on to every little price increase only to see it fall again.
AIM, a passport from optimism and youth to pessimism and old age. Many of us have died waiting.